If you've spent more than five minutes researching GLP-1 medications, you've run into the Ozempic vs. Wegovy question. And you've probably noticed they're both made by Novo Nordisk, both contain semaglutide, and yet they're marketed and priced as completely different products.
The confusion is understandable. Here's exactly what's going on.
The Simple Truth: Same Molecule, Different Doses and Indications
Ozempic and Wegovy are both semaglutide. Same active ingredient. Same mechanism. Same manufacturer. Different FDA approval indications and different maximum doses.
Ozempic (approved 2017): - Indication: Type 2 diabetes management - Available doses: 0.5mg, 1mg, 2mg weekly - Primary endpoint: HbA1c reduction - Weight loss: occurs as a secondary benefit - Insurance coverage: generally available for T2D patients
Wegovy (approved 2021): - Indication: Chronic weight management - Available doses: up to 2.4mg weekly - Primary endpoint: % body weight reduction - Weight loss: the primary goal - Insurance coverage: more variable; many plans still exclude it
The 0.4mg difference in max dose (2mg vs 2.4mg) explains about 1-2% additional average weight loss in favor of Wegovy. The bigger practical difference is how insurance treats each for different indications.
The Clinical Trial Numbers
The STEP trials (Wegovy) vs. the SUSTAIN trials (Ozempic) give us the comparison data:
STEP 1 (Wegovy 2.4mg, 68 weeks): Average weight loss = 14.9% of body weight SUSTAIN 6 (Ozempic 2mg, 104 weeks): Average weight loss = 8.2% (in T2D patients with cardiovascular disease) SCALE Maintenance (earlier semaglutide trial, 2.4mg equivalent): 13.8% weight loss
The Wegovy number looks dramatically better at first glance, but context matters: the SUSTAIN 6 trial was in diabetic patients with cardiovascular disease who had different baseline characteristics. Controlled comparisons at similar doses show a modest Wegovy advantage that narrows significantly at 2mg.
Bottom line: At the same dose, the weight loss effect is essentially identical — because it's the same drug. Wegovy's higher max dose gives it a slight edge for patients who tolerate 2.4mg.
Why Ozempic Gets Prescribed Off-Label for Weight Loss
Physicians have been prescribing Ozempic off-label for weight loss since its approval, particularly as Wegovy faced supply shortages. This is medically legitimate and common practice. The clinical evidence for semaglutide's weight loss effect existed long before Wegovy's approval — Novo Nordisk simply pursued separate FDA approvals for the same molecule at different dose levels.
The off-label use does come with a pricing quirk: in some cases, insurance will cover Ozempic for a diabetes indication but won't cover Wegovy for weight loss. This leads to the absurd situation where patients can sometimes access the same drug cheaper by having a diabetes diagnosis.
Where Compounded Semaglutide Changes the Math
Both Ozempic and Wegovy have retail list prices of $900-$1,400/month without insurance. This pricing has nothing to do with the cost of manufacturing semaglutide — it reflects patent protection and the absence of competition.
Compounded semaglutide (available through telehealth providers like [Marrow](/semaglutide)) runs $179-$399/month depending on dose. It's the same active molecule, manufactured at FDA-registered compounding pharmacies, and prescribed through the same physician oversight framework.
The only thing you lose with compounded semaglutide: the Novo Nordisk brand name and the auto-injector pen design. The medicine is identical.
Which Should You Actually Ask For?
For most patients pursuing weight loss through telehealth, the question of Ozempic vs. Wegovy is moot. You're getting compounded semaglutide — which doesn't carry either brand name and is available at any dose your physician determines is clinically appropriate, including up to 2.4mg weekly.
If you're navigating insurance: - Have type 2 diabetes? → Ozempic is the natural starting point. Weight loss will happen. - No diabetes, strong insurance? → Push for Wegovy coverage. Some plans cover it now. - Paying out of pocket? → Compounded semaglutide is the obvious answer — same molecule, 70-80% cheaper.
The Ozempic vs. Wegovy debate mostly exists because of insurance coding and drug pricing strategy, not because there's a meaningful clinical difference between the two. Don't overthink it.
[Start your semaglutide intake at Marrow](/start) — our physicians determine the appropriate dose and protocol based on your individual situation.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both are injectable semaglutide, but for different indications: Ozempic is approved for type 2 diabetes management (max 2mg weekly), while Wegovy is approved for chronic weight management (max 2.4mg weekly). The higher max dose in Wegovy produces greater average weight loss.
Can I use Ozempic for weight loss instead of Wegovy?
Physicians regularly prescribe Ozempic off-label for weight loss. At the doses typically used for diabetes (0.5-2mg), it produces meaningful weight loss — just slightly less than the 2.4mg Wegovy dose in most patients.
Why does Wegovy cost more than Ozempic if they're the same drug?
Novo Nordisk priced them as different products targeting different markets. Ozempic had established insurance coverage for diabetes; Wegovy is a newer launch for obesity with different insurance dynamics. Compounded semaglutide avoids both price points entirely.
Which produces more weight loss, Ozempic or Wegovy?
Wegovy at 2.4mg produces slightly greater average weight loss than Ozempic at its max dose of 2mg — roughly 15% vs. 13% in clinical trials. The difference is real but not dramatic for most patients.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
